|
|
News Breaks | | | | January 29, 2013 | | 07:01 EDT |  | SHPG | Shire price target range raised to $114-$115 at Leerink
Leerink raised its price target range for Shire shares to $114-$115 from $103-$104 citing strong demand for Firazyr in hereditary angioedema and increased estimates for Vyvanse in ADHD. The firm keeps an Outperform rating on the stock. | |
|
News For SHPG From The Last 14 Days Check below for free stories on SHPG the last two weeks. |
|
|
| May 14, 2013 | | 07:24 EDT |  | SHPG | EBD Group to host a conference
BioTrinity 2013 is being held in Newbury, England on May 14-16. | | | May 10, 2013 | | 10:00 EDT |  | SHPG | On The Fly: Analyst Downgrade Summary
 Subscribe for More Information | | | 05:42 EDT | | SHPG | Shire downgraded to Neutral from Overweight at JPMorgan
| | | May 9, 2013 | | 12:24 EDT |  | SHPG | Shire unit wins patent trial against Watson regarding LIALDA
Shire (SHPG), announces that its subsidiary, Shire Development, has prevailed in its litigation against Watson Pharmaceuticals, Watson Laboratories-Florida, Watson Pharma. and Watson Laboratories in connection with their Abbreviated New Drug Application for a generic version of Shire's LIALDA delayed release tablets for the induction of remission in adults with active, mild to moderate ulcerative colitis and for the maintenance of remission of ulcerative colitis. Following a five day bench trial in the Southern District of Florida, Judge Middlebrooks issued a ruling upholding the validity of the patent covering LIALDA, US Patent No. 6,773,720, and holding that the proposed ANDA formulation infringes the claims of that patent. Accordingly, Judge Middlebrooks confirmed that Shire is entitled to an injunction, which he will issue separately, which prohibits the FDA from approving the ANDA formulation until the expiration of the '720 patent. | | | 10:17 EDT |  | SHPG | Shire trades higher in London amid takeover chatter, Guardian says
Subscribe for More Information | |
|
|
|
|
|
|
